CNBG-Virogin Biotech (Shanghai) Co., Ltd has announced obtaining clinical trial approval from the National Medical Products Administration (NMPA) for its Omicron variant-targeted mRNA vaccine. This marks a significant milestone in the development of COVID-19 vaccines tailored to emerging variants.
Vaccine Development and Innovation
The product, China’s first COVID-19 mRNA vaccine encoding the Omicron S protein, features a novel antigen design aimed at enhancing the induction of effective neutralizing antibodies. Preclinical studies demonstrated the vaccine’s complete protective effect in susceptible animal models, highlighting its potential efficacy against the Omicron variant.
Manufacturing and Technology
Virogin Bio will leverage its advanced mRNA-LNP (lipid nanoparticle) packaging technology to ensure robust and scalable manufacturing of the vaccine. This technology is crucial for maintaining the stability and delivery efficiency of mRNA vaccines, positioning CNBG-Virogin to contribute significantly to the global fight against COVID-19.-Fineline Info & Tech
